ARCS Australia builds capacity to support clinical trials during the COVID-19 pandemic

Health Industry Hub | May 6, 2020 |
[Total: 1    Average: 5/5]

The COVID-19 pandemic has had a major impact on the conduct of clinical trials worldwide, including in Australia.

In an interview with Health Industry Hub, Dr Shanny Dyer, CEO of ARCS Australia discussed the impact of the turbulent COVID-19 environment on new and existing clinical trials in Australia, the important support provided by the ARCS Clinical Trials Volunteer Program and the critical role that Pharma, Biotech and MedTech industries can play in continuing clinical trials to bring life-saving treatments to patients.

Interview with Dr Shanny Dyer, CEO of ARCS Australia

ARCS Clinical Trials Volunteer Program

ARCS Australia is calling for volunteers to assist with the support of current clinical trials and any new COVID-19 related trials. In particular, ARCS is looking for non-clinical professionals who can support the administrative aspects of clinical trials and the associated project management.

ARCS Australia has already received over 100 expressions of interest to volunteer. The majority of volunteers are from universities (30%), followed by hospitals, research institutes and industry.

Professor Jennifer Martin, Chair of Clinical Pharmacology and School of Medicine and Public Health at the University of Newcastle has seen a reallocation of hospital beds and resources during COVID-19 which has paused patient recruitment or resulted in a delay of existing clinical trials where patients would need to come in to hospital to receive their treatment.

“We didn’t have the clinical trial nurses or expert input to help us write the protocol for a new study. Once we were put in touch with ARCS Australia, within a day they said they had volunteers to help us with our trial. We were ecstatic and just delighted,” said Professor Martin.

At the conclusion of her interview Dr Dyer said “Australia is in a unique position in that the impact of the COVID-19 pandemic, whilst serious, has been well controlled by Government. We are in a very good position to deliver clinical trials in Australia. The key message is that Australia is open for clinical trials ensuring the safety of patients and the staff, and the integrity of the data is maintained. We know clinical trials save lives and are an important part of healthcare services in Australia. Let’s keep working together and keep clinical trials going. We will come out of this bigger and stronger.”

Dr Shanny Dyer (left) and Professor Jennifer Martin (right)

Register FREE and join 22,000+ industry professionals receiving the latest industry news and engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Leadership & Management

Leadership Management Qualities - COVID-19 wiping out hard-won gains by women in STEM

COVID-19 wiping out hard-won gains by women in STEM

Health Industry Hub | June 1, 2020 |

Hard-won gains for women’s advancement in the science, technology, engineering and maths (STEM) workforce are now at risk of a […]


News & Trends - Medical Technology

MedTech News - New agreement to end public hospitals' “harvesting” of privately insured patients

New agreement to end public hospital “harvesting” of privately insured patients

Health Industry Hub | June 1, 2020 |

MedTech News: The new National Health Reform Agreement has the potential to end the practice of public hospitals “harvesting” privately […]


News & Trends - Pharmaceuticals

Pharma News - GSK's targeted therapy for asthma gains PBS listing for self-administration delivery

GSK’s targeted therapy for asthma gains PBS listing for self-administration delivery

Health Industry Hub | June 1, 2020 |

Pharma News: From 1 June 2020, GSK Australia’s new pre-filled pen (autoinjector) for the self-administration of its targeted therapy for […]


News & Trends - Pharmaceuticals

Pharma News - Major changes to opioid PBS listings effective 1 June

Major changes to opioid PBS listings effective 1 June

Health Industry Hub | June 1, 2020 |

Commencing 1 June 2020, the Pharmaceutical Benefits Scheme (PBS) listings for opioid medicines will change including Tramal (tramadol) and Panadeine […]